What the studies show
The use it is most often sold for. A search of the trial literature finds no controlled study of gonadorelin added to testosterone replacement for testicular size, fertility or hormone recovery. The physiological rationale is that intermittent GnRH could keep the pituitary signalling; continuous GnRH does the opposite and shuts it down, which is how the same molecule's analogues treat prostate cancer.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Wei C, Long G, Zhang Y, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis.World J Mens Health, 2021;39(4):654–6657 studies, 420 men; mostly non-randomised.
- 2Searches of PubMed and trial registries for gonadorelin added to testosterone replacement therapy.LYO literature search, September 2026No controlled trial of the TRT use identified.
In context
Gonadorelin is synthetic gonadotropin-releasing hormone, the ten-amino-acid signal the hypothalamus sends to make the pituitary release LH and FSH. Given in pulses by pump it restores fertility in men and women whose own signal is missing; given once it is a licensed test of pituitary function. Neither is what it is mostly sold for today: clinics add it to testosterone replacement to 'keep the testes working', a use that has never been tested in a trial. It is prohibited for male athletes.
Gonadorelin (GnRH) is licensed (diagnostic / pulsatile); trt use unstudied. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Gonadorelin (GnRH) proven to help with preserving testicular function on testosterone therapy?
What studies are behind the grade?
Is Gonadorelin (GnRH) approved for this?
Other outcomes for Gonadorelin (GnRH)
- ALH and FSH release (diagnostic)Approval-grade
- BFertility in hypogonadotropic hypogonadism (pulsatile pump)7 comparative studies, 420 men (meta-analysis); many small series
- BAdverse effectsadversePulsatile-therapy series
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →